Pfizer weighs sale of consumer healthcare business
Pfizer is considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth some $15 billion up for grabs.
Business
• 11 Oct 17
